Prokidney Corp.
PROK- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850270
In the last 90 days, Prokidney Corp. insiders filed 0 open-market purchases and 1 sale; 90 institutions reported holding it in 13F filings for Q3 2026, worth $92.0M in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.07M in total
- 1
- 13F holdersQ3 2026, +20 vs. previous quarter
- 90
- 13F valueReported value at the end of Q3 2026
- $92.0M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $893.0K
- +1,075.0% year over year
- Net income, FY2025
- -$69.0M
- No comparable prior period
- Free cash flow, FY2025
- -$135.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $174.0K
- −19.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $69.0M (7725.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 24.3M
- Shares sold short
- Change
- −230.2K
- −0.9% vs. previous
- Days to cover
- 22.51
- At average daily volume
Superinvestors holding PROK, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding PROK at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Prokidney Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)5:00 PM ET | Aug 18-20 | 2 days | Pereira Brian JGDirector | SSaleClass A Common Stock | −675.2K | $1.41 | −$952.2K | −100.0%0 after | 3 lots |
| Aug 20, 2026 (view filing)5:00 PM ET | Aug 18-20 | 2 days | Pereira Brian JGDirector | SSaleClass A Common Stock | −81.9K | $1.41 | −$115.5K | −100.0%0 after | 3 lots |
| Nov 14, 2025 (view filing) | Nov 12-13 | 2 days | Pereira Brian JGDirector | SSaleClass A Common Stock | −757.2K | $2.49 | −$1.88M | −100.0%0 after | 4 lots |
| Jul 9, 2025 (view filing) | Jul 8 | 1 day | Weber Darin J.Chief Regulatory Officer | SSaleClass A Common Stock | −103.5K | $3.02 | −$312.5K | −100.0%0 after | 10b5-1 |
| Apr 24, 2025 (view filing) | Apr 22 | 2 days | Control Empresarial de Capitales S.A. de C.V.10% Owner, Other: Add'l Rep. Persons-see Ex.99-1 | PPurchaseClass A Ordinary Shares (as defined in Exhibit 99.1 hereto) | +387.4K | $0.71 | +$275.0K | +0.5%73.8M after | |
| Apr 21, 2025 (view filing) | Apr 17 | 4 days | Control Empresarial de Capitales S.A. de C.V.10% Owner, Other: Add'l Rep. Persons-see Ex.99-1 | PPurchaseClass A Ordinary Shares (as defined in Exhibit 99.1 hereto) | +25.0K | $0.75 | +$18.8K | 0.0%73.5M after | |
| Apr 18, 2025 (view filing) | Apr 16 | 2 days | Control Empresarial de Capitales S.A. de C.V.10% Owner, Other: Add'l Rep. Persons-see Ex.99-1 | PPurchaseClass A Ordinary Shares (as defined in Exhibit 99.1 hereto) | +100.0K | $0.75 | +$75.0K | +0.1%73.4M after | |
| Apr 16, 2025 (view filing) | Apr 14-15 | 2 days | Control Empresarial de Capitales S.A. de C.V.10% Owner, Other: Add'l Rep. Persons-see Ex.99-1 | PPurchaseClass A Ordinary Shares (as defined in Exhibit 99.1 hereto) | +736.1K | $0.7109 | +$523.3K | +1.0%73.3M after | 2 lots |
| Apr 14, 2025 (view filing) | Apr 10-11 | 4 days | Control Empresarial de Capitales S.A. de C.V.10% Owner, Other: Add'l Rep. Persons-see Ex.99-1 | PPurchaseClass A Ordinary Shares (as defined in Exhibit 99.1 hereto) | +1.03M | $0.61 | +$630.8K | +1.4%72.6M after | 2 lots |
| Sep 20, 2024 (view filing) | Sep 19 | 1 day | Weber Darin J.Chief Regulatory Officer | SSaleClass A Ordinary Shares | −16.4K | $2.50 | −$41.0K | −13.7%103.5K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 90 holdersThe largest institutional positions in Prokidney Corp. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12,341,266 | $20.5M | 0.56% | 00.0% | Unchanged |
| Morgan Stanley | 9,850,142 | $16.4M | 0.00% | −4,0360.0% | Reduced |
| BlackRock, Inc. | 7,971,695 | $13.2M | 0.00% | +2,774,468+53.4% | Added |
| Geode Capital Management, LLC | 3,590,979 | $5.96M | 0.00% | +1,200,832+50.2% | Added |
| Propel Bio Management, LLC | 2,009,733 | $3.34M | 1.77% | +2,009,733 | New |
| Bleichroeder LP | 1,900,000 | $3.15M | 0.31% | −100,000−5.0% | Reduced |
| State Street Corp | 1,810,345 | $3.01M | 0.00% | +764,400+73.1% | Added |
| Hennion & Walsh Asset Management, Inc. | 1,806,553 | $3.00M | 0.09% | −41,196−2.2% | Reduced |
| Vanguard Capital Management LLC | 1,726,762 | $2.87M | 0.00% | +551,505+46.9% | Added |
| Charles Schwab Investment Management Inc | 1,354,874 | $2.25M | 0.00% | +573,145+73.3% | Added |
Holders of 5% or more of PROK
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Prokidney Corp..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tolerantia, LLC | 13D/A | 36.50%106.9M shares | −1.50 ppfrom 38.00% | Jul 22, 20226 filings | Jun 5, 2025 | SEC |
| Control Empresarial de Capitales S.A. de C.V. | 13D/A | 36.00%73.8M shares | – | Jul 22, 20223 filings | Apr 30, 2026 | SEC |